22 Results for "

LN229

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "LN229" in MCE Product Catalog:

24
24 Publications Verification
Cat. No.: HY-18777
CAS No.: 927822-86-4
Research Areas:  

Cancer

KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC50 of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12970A
CAS No.: 2070015-25-5
Purity:  98.15%
EPZ020411 hydrochloride is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC50 of 0.010 μM. EPZ020411 hydrochloride blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 hydrochloride is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12494
CAS No.: 1361030-48-9
Purity:  99.64%
Target:  

TAM Receptor FLT3

Research Areas:  

Neurological Disease Cancer

LDC1267 is a AXL/TAM/FLT3 inhibitor with IC50 values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12970
CAS No.: 1700663-41-7
Purity:  98.07%
EPZ020411 is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC50 of 0.010 μM. EPZ020411 blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0826
CAS No.: 18797-79-0
Corynoline is an orally active acetylcholinesterase (AChE) inhibitor with an IC50 of 30.6 μM. Corynoline exhibits multiple activities including anti-inflammatory, antinociceptive, antitumor and analgesic effects. Corynoline can be used in the research of diseases such as tumors and inflammatory pain .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12855A
CAS No.: 1391426-24-6
Purity:  99.89%
Synonyms: Lys01 trihydrochloride
Target:  

Autophagy

Research Areas:  

Cancer

Lys05 (Lys01 trihydrochloride) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108637A
CAS No.: 1050480-30-2
Purity:  99.01%
Target:  

MDM-2/p53

Research Areas:  

Cancer

PhiKan 083 hydrochloride is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM , and a relative binding affinity (Kd) of 150 μM in Ln229 cells .
loading...
    loading...
Cat. No.: HY-131943
CAS No.: 2361327-08-2
Purity:  99.36%
DS44960156 is a selective MTHFD2 inhibitor with moderate to low blood-brain barrier penetration (IC50=1.6 μM, Ki=1.23 μM). DS44960156 specifically binds to the active site of MTHFD2, disrupts redox homeostasis and blocks serine-mediated one-carbon metabolism, thereby increasing the NAD +/NADH ratio and ROS levels. DS44960156 not only effectively inhibits the proliferation of glioma cells, but also enhances the sensitivity of cells to glutamine starvation-induced death. DS44960156 binds to plasma proteins, shows no mutagenicity, carcinogenicity or acute oral toxicity, and serves as a research agent for glioblastoma multiforme and other cancers .
loading...
    loading...
Cat. No.: HY-155888
CAS No.: 3057089-47-8
Purity:  98.41%
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
loading...
    loading...
Cat. No.: HY-W278944
CAS No.: 19819-18-2
Target:  

Drug Derivative

Research Areas:  

Cancer

Antiproliferative agent-15 is an thienopyrimidine derivated anticancer agent. Antiproliferative agent-15 shows antiproliferative activity against human colon (HCT116 and HCT15) and brain (LN-229 and GBM-10) cancer cell lines .
loading...
    loading...
Cat. No.: HY-113916
CAS No.: 1019889-35-0
Synonyms: AT13387 lactate
Target:  

HSP

Research Areas:  

Cancer

Onalespib lactate is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor with an Kd value of 0.71 nM. Onalespib lactate inhibits the proliferation, survival and migration. Onalespib lactate decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib lactate shows antitumor activity. Onalespib lactate has the potential for the research of non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-123009
CAS No.: 927823-01-6
KCN1 is a p300/HIF-1α interaction inhibitor with a Kd value of 345 nM for p300-CH1. KCN1 binds to the CH1 domain of p300, blocks the assembly of the p300/HIF-1α complex, and disrupts the HIF-1α-p300/CBP interaction. KCN1 inhibits cancer cell growth, induces cancer cell cycle arrest and apoptosis. KCN1 inhibits β-galactosidase activity and downregulates the expression of VEGF, Glut1, CA9 and CAIX. KCN1 exerts anticancer activity in mouse tumor xenograft models. KCN1 can be used in research related to malignant glioma, pancreatic cancer and metastatic uveal melanoma .
loading...
    loading...
Cat. No.: HY-18259
CAS No.: 773852-25-8
Research Areas:  

Cancer

103D5R (Compound 15) is an inhibitor for the activation of hypoxia-inducible factor-1 (HIF-1) with an IC50 of 35 µM, through reduction of the HIF-1α protein synthesis. 103D5R inhibits the proliferation of LN229 with IC50 of 26 µM .
loading...
    loading...
Cat. No.: HY-168721
CAS No.: 63589-51-5
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Tubulin inhibitor 48 (compound 16) is an anti-cancer agent targeting tubulin. Tubulin inhibitor 48 has an IC50 of 0.1 and 0.07 μM for LN-229 and Capan-1 cell, respectively .
loading...
    loading...
Cat. No.: HY-12855
CAS No.: 1391426-22-4
Target:  

Autophagy

Research Areas:  

Cancer

Lys01, a dimeric form of Chloroquine (HY-17589A), is an autophagy inhibitor. Lys01 inhibits cell viability of 1205Lu, c8161, LN229, HT-29 cells with IC50s of 3.6, 3.8, 7.9, 6.0 μM. Lys01 can be used for anticancer research .
loading...
    loading...
Cat. No.: HY-161303
CAS No.: 2923208-52-8
Research Areas:  

Cancer

ZNF207-IN-1 is an orally active and brain-penetrant ZNF207 inhibitor with a target KD of 67 nM. ZNF207-IN-1 binds directly to ZNF207, downregulates stem-related genes and weakens glioma cell stemness. ZNF207-IN-1 hinders tumorigenesis and migration and promotes apoptosis. ZNF207-IN-1 can be used for the research of glioma[1].
loading...
    loading...
Cat. No.: HY-149515
CAS No.: 797805-26-6
Target:  

Monoamine Oxidase

Research Areas:  

Cancer

MAO-IN-3 (Compound 5) is a reversible and competitive MAO inhibitor (Ki: 0.6 and 0.2 μM for MAO A and MAO B). MAO-IN-3 inhibits LN-229 glioblastoma cell proliferation with an IC50 of 0.8 μM. MAO-IN-3 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-178140
CAS No.: 2787548-58-5
Target:  

STAT

Research Areas:  

Cancer

STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-155464
Target:  

VEGFR Aurora Kinase

Research Areas:  

Cancer

VEGFR-2/AURKA-IN-1 (compound 5e) is a thiazolidin-4-one derivative with antiglioma activity (IC50: 6.43 μM, LN229). VEGFR-2/AURKA-IN-1 has affinity for AURKA and VEGFR-2 and is a potential ligand. VEGFR-2/AURKA-IN-1 causes DNA strand breaks and exhibits cytotoxic and anticancer potential .
loading...
    loading...
Cat. No.: HY-155889
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
loading...
    loading...